We are live on ! Find out more
IMGN

Immunogen Inc

Delisted

IMGN was delisted on the 9th of February, 2024.

208 hedge funds and large institutions have $1.18B invested in Immunogen Inc in 2018 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 61 increasing their positions, 61 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

660% more call options, than puts

Call options by funds: $16.9M | Put options by funds: $2.22M

37% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 27

5% more funds holding

Funds holding: 198208 (+10)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 61

3% less capital invested

Capital invested by funds: $1.22B → $1.18B (-$41.6M)

Holders
208
Holders Change
+10
Holders Change %
+5.05%
% of All Funds
4.76%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
37
Increased
61
Reduced
61
Closed
27
Calls
$16.9M
Puts
$2.22M
Net Calls
+$14.6M
Net Calls Change
+$14.6M
Name Holding Trade Value Shares
Change
Change in
Stake
State Board of Administration of Florida Retirement System
76
State Board of Administration of Florida Retirement System
Florida
$734K
CM
77
Caption Management
Oklahoma
$732K +$743K +77,250 New
Barclays
78
Barclays
United Kingdom
$722K +$544K +56,640 +290%
Stifel Financial
79
Stifel Financial
Missouri
$717K +$22.2K +2,311 +3%
AQR Capital Management
80
AQR Capital Management
Connecticut
$678K +$16.4K +1,701 +2%
N
81
Nuveen
North Carolina
$654K +$68.8K +7,153 +12%
BTS
82
BB&T Securities
Virginia
$645K -$47.8K -4,972 -7%
ECM
83
Endurant Capital Management
California
$607K -$40.4K -4,200 -6%
TD Asset Management
84
TD Asset Management
Ontario, Canada
$604K -$81.7K -8,500 -12%
EIM
85
Essex Investment Management
Massachusetts
$584K +$593K +61,676 New
Assenagon Asset Management
86
Assenagon Asset Management
Luxembourg
$579K +$587K +61,112 New
MIM
87
MetLife Investment Management
New Jersey
$566K
DekaBank Deutsche Girozentrale
88
DekaBank Deutsche Girozentrale
Germany
$562K -$14.4K -1,500 -3%
CI
89
Cavalier Investments
Georgia
$536K +$544K +56,600 New
MSL
90
Mackay Shields LLC
New York
$528K +$97.1K +10,100 +22%
CEP
91
Chicago Equity Partners
Illinois
$474K -$4.58M -476,654 -91%
ARTA
92
A.R.T. Advisors
New York
$461K +$469K +48,745 New
MLICM
93
Metropolitan Life Insurance Company (MetLife)
New York
$445K +$46.4K +4,824 +11%
Simplex Trading
94
Simplex Trading
Illinois
$429K +$157K +16,321 +56%
VEA
95
Virtus ETF Advisers
New York
$427K -$310K -32,253 -42%
GC
96
Grace Capital
Massachusetts
$375K
Two Sigma Investments
97
Two Sigma Investments
New York
$368K +$374K +38,871 New
JP Morgan Chase
98
JP Morgan Chase
New York
$338K +$75.3K +7,837 +28%
LPL Financial
99
LPL Financial
California
$302K -$1.49K -155 -0.5%
Wolverine Trading
100
Wolverine Trading
Illinois
$294K +$298K +31,000 New

IMGN Hedge Fund Activity: Q3 2018 in Review

208 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Immunogen Inc (IMGN) for Q3 2018, worth a combined $1.18B — down 3.4% from $1.22B a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new IMGN positions and 27 closed out — a net gain of 10 holders — while 61 added to existing stakes and 61 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $39.6M. The largest seller was Capital Research Global Investors, cutting an estimated $22.5M.

  • 208 institutional investors held Immunogen Inc (IMGN) as of Q3 2018, up from 198 in Q2 2018.
  • Funds reported $1.18B of Immunogen Inc stock for Q3 2018, down 3.4% quarter-over-quarter.
  • 37 funds opened new Immunogen Inc positions in Q3 2018 and 27 closed out, a net change of +10 holders.
  • The largest Immunogen Inc buyer in Q3 2018 was Point72 Asset Management, an estimated $39.6M added.
  • The largest Immunogen Inc seller in Q3 2018 was Capital Research Global Investors, an estimated $22.5M sold.

Based on aggregated 13F filings for Q3 2018.